SCHEMBL2574381

SCHEMBL2574381

COCCNCCc1cc(NCc2ccccc2)c([N+](=O)[O-])c(NCc2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.46
LMNA P02545 4/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 3/20 0.44
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 3/20 0.44
MAPK1 P28482 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
BLM P54132 2/20 0.44
RECQL P46063 1/20 0.44
EGFR P00533 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.40
CRHBP P24387 2/20 0.40
KMT2A Q03164 2/20 0.40
CRHR2 Q13324 2/20 0.40
GAA P10253 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572273 0.91 MAPT (0.50) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2567876 0.81 MAPT (0.53) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2564349 0.79 LMNA (0.41) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2572337 0.79 MAPT (0.53) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2572361 0.78 MAPT (0.55) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL13407309 0.77 MAPT (0.59) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2573075 0.76 MAPT (0.55) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2573379 0.75 MAPT (0.51) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL2571273 0.74 MAPT (0.58) MAPTLMNAHPGDHTTALDH1A1
SCHEMBL12164325 0.73 MAPT (0.57) MAPTLMNAHPGDHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987030-B1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LTD (GB) 2011-11-09 EP disclosed
US-7691877-B2 Pharmaceuticals PFIZER INC. (US) 2010-04-06 US disclosed
US-20070197478-A1 NOVEL PHARMACEUTICALS PFIZER LIMITED 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197478-A1 NOVEL PHARMACEUTICALS TLR3, HAVCR2, TLR9 MAPT 4363/4885LMNA 4120/4885HPGD 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.